Skip to main content

Lipid accumulation product and metabolic syndrome: a population-based study in northern Iran, Amol

Journal of Endocrinological Investigation volume 39, pages 375–382 (2016)Cite this article

Abstract

Purpose

Lipid accumulation product (LAP) demonstrated a strong predictive accuracy for metabolic syndrome (MetS) in previous studies. This study was conducted to determine the predictive performance of LAP compared to obesity indexes. Moreover, the optimal cutoff point of LAP based on the study population waist circumference threshold was estimated in both men and women.

Methods

5797 subjects with an average age of 44.77 ± 16.77 years for men and 43.78 ± 15.43 years for women were included in the present study. The ROC analysis was performed to assess the predictive accuracy of LAP in the diagnosis of MetS. The optimal cutoff point of LAP was determined according to maximal Youden index in both men and women.

Results

The optimal cutoff points determined for LAP were 49.71 (sensitivity = 85.2 %, specificity = 82.3 %) for women and 39.89 (sensitivity = 86 %, specificity = 79.6 %) for men. Based on the assigned cutoff points, the prevalence of high LAP was obtained 44.1 % in men and 45.1 % in women. LAP also showed a significantly higher predictive performance for MetS compared to obesity measures and also TG.

Conclusion

LAP has a strong and reliable diagnostic accuracy for MetS in Iranian population in the north of Iran. LAP showed a better predictability than other obesity indexes assessed in the present study.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. (2006) International Diabetes Federation: the IDF consensus worldwide definition of the metabolic syndrome. http://www.idf.org/metabolic-syndrome

  2. Gallagher EJ, LeRoith D, Karnieli E (2011) The metabolic syndrome—from insulin resistance to obesity and diabetes. Med Clin N Am 95(5):855–873

    CAS  Article  PubMed  Google Scholar 

  3. Beltrán-Sánchez H, Harhay MO, Harhay MM, McElligott S (2013) Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999–2010. J Am Coll Cardiol 62(8):697–703. doi:10.1016/j.jacc.2013.05.064

    Article  PubMed  PubMed Central  Google Scholar 

  4. Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. J Am Med Assoc 287:356–359

    Article  Google Scholar 

  5. Bozorgmanesh M, Hadaegh F, Azizi F (2010) Predictive performances of lipid accumulation product vs. adiposity measures for cardiovascular diseases and all-cause mortality, 8.6-year follow-up: Tehran lipid and glucose study. Lipids Health Dis 16(9):100

    Article  Google Scholar 

  6. Bozorgmanesh M, Hadaegh F, Azizi F (2010) Diabetes prediction, lipid accumulation product, and adiposity measures; 6-year follow-up: Tehran lipid and glucose study. Lipids Health Dis 10(9):45

    Article  Google Scholar 

  7. Yun JE, Won S, Sung J, Jee SH (2012) Impact of metabolic syndrome independent of insulin resistance on the development of cardiovascular disease. Circ J 76(10):2443–2448 Epub 2012 Jul 12

    CAS  Article  PubMed  Google Scholar 

  8. Oladejo AO (2011) Overview of the metabolic syndrome; an emerging pandemic of public health significance. Ann Ib Postgrad Med 9(2):78–82

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA (2004) Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 109(4):551–556

    Article  PubMed  Google Scholar 

  10. Kahn HS (2005) The “lipid accumulation product” performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord 8(5):26

    Article  Google Scholar 

  11. Xia C, Li R, Zhang S, Gong L, Ren W, Wang Z, Li Q (2012) Lipid accumulation product is a powerful index for recognizing insulin resistance in non-diabetic individuals. Eur J Clin Nutr 66(9):1035–1038

    CAS  Article  PubMed  Google Scholar 

  12. Chiang JK, Koo M (2012) Lipid accumulation product: a simple and accurate index for predicting metabolic syndrome in Taiwanese people aged 50 and over. BMC Cardiovasc Disord 24(12):78

    Article  Google Scholar 

  13. Zamani F, Sohrabi M, Alipour A, Motamed N, Saeedian FS, Pirzad R, Abedi K, Maadi M, Ajdarkosh H, Hemmasi G, Khonsari M (2014) Prevalence and risk factors of cholelithiasis in Amol city, northern Iran: a population based study. Arch Iran Med 17(11):750–754. doi:0141711/AIM.006

  14. Alberti KG, Zimmet P, Shaw J (2006) Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabetic Med 23(5):469–480

    CAS  Article  PubMed  Google Scholar 

  15. Expert Panel on Detection, Evaluation (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285(19):2486–2497

    Article  Google Scholar 

  16. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16):1640–1645

    CAS  Article  PubMed  Google Scholar 

  17. Taverna MJ, Martínez-Larrad MT, Frechtel GD, Serrano-Ríos M (2011) Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population. Eur J Endocrinol 164(4):559–567. doi:10.1530/EJE-10-1039

    CAS  Article  PubMed  Google Scholar 

  18. Tellechea ML, Aranguren F, Martínez-Larrad MT, Serrano-Ríos M, Taverna MJ, Frechtel GD (2009) Ability of lipid accumulation product to identify metabolic syndrome in healthy men from Buenos Aires. Diabetes Care 32(7):e85. doi:10.2337/dc08-2284

    Article  PubMed  Google Scholar 

  19. Wakabayashi I, Daimon T (2014) A strong association between lipid accumulation product and diabetes mellitus in japanese women and men. J Atheroscler Thromb 21(3):282–288

    Article  PubMed  Google Scholar 

  20. Xiang S, Hua F, Chen L, Tang Y, Jiang X, Liu Z (2013) Lipid accumulation product is related to metabolic syndrome in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 121(2):115–118. doi:10.1055/s-0032-1333261

    CAS  Article  PubMed  Google Scholar 

  21. Hosseinpanah F, Barzin M, Mirbolouk M, Abtahi H, Cheraghi L, Azizi F (2014) Lipid accumulation product and incident cardiovascular events in a normal weight population: Tehran lipid and glucose study. Eur J Prev Cardiol [Epub ahead of print]

  22. Bener A, Yousafzai MT, Darwish S, Al-Hamaq AO, Nasralla EA, Abdul-Ghani M (2013) Obesity index that better predict metabolic syndrome: body mass index, waist circumference, waist hip ratio, or waist height ratio. J Obes 2013:269038. doi:10.1155/2013/269038

    Article  PubMed  PubMed Central  Google Scholar 

  23. Ghazali SM, Sanusi RA (2010) Waist circumference, waist to hip ratio, and body mass index in the diagnosis of metabolic syndrome in Nigerian subjects. Niger J Physiol Sci 25(2):187–195

    CAS  PubMed  Google Scholar 

  24. Wang F, Wu S, Song Y, Tang X, Marshall R, Liang M, Wu Y, Qin X, Chen D, Hu Y (2009) Waist circumference, body mass index and waist to hip ratio for prediction of the metabolic syndrome in Chinese. Nutr Metab Cardiovasc Dis 19(8):542–547

    CAS  Article  PubMed  Google Scholar 

  25. Wiltgen D, Benedetto IG, Mastella LS, Spritzer PM (2009) Lipid accumulation product index: a reliable marker of cardiovascular risk in polycystic ovary syndrome. Hum Reprod 24(7):1726–1731

    CAS  Article  PubMed  Google Scholar 

  26. Xia C, Li R, Zhang S, Gong L, Ren W, Wang Z, Li Q (2012) Lipid accumulation product is a powerful index for recognizing insulin resistance in non-diabetic individuals. Eur J Clin Nutr 66(9):1035–1038

    CAS  Article  PubMed  Google Scholar 

  27. Wehr E, Gruber HJ, Giuliani A, Möller R, Pieber TR, Obermayer-Pietsch B (2011) The lipid accumulation product is associated with impaired glucose tolerance in PCOS women. J Clin Endocrinol Metab 96(6):E986–E990. doi:10.1210/jc.2011-0031

    CAS  Article  PubMed  Google Scholar 

  28. Hosseinpanah F, Barzin M, Erfani H, Serahati S, Ramezani Tehrani F, Azizi F (2014) Lipid accumulation product and insulin resistance in Iranian PCOS prevalence study. Clin Endocrinol (Oxf) 81(1):52–57

    CAS  Article  Google Scholar 

Download references

Acknowledgments

This study was supported by Iran University of Medical Sciences (IUMS). We would like to thank the cooperation of Amol Hefadah Shahrivar Hospital’s staff, health care centers.

Author information

Affiliations

  1. Department of Social Medicine, Zanjan University of Medical Science, Zanjan, Iran

    N. Motamed

  2. Department of Neuroscience, Carleton University, Ottawa, Canada

    S. Razmjou

  3. Gastrointestinal and Liver Disease Research Center (GILDRC), Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran

    S. Razmjou, G. Hemmasi, M. Maadi & F. Zamani

Authors
  1. N. Motamed
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Razmjou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Hemmasi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Maadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Zamani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Zamani.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest.

Ethical approval

The ethical approval for this study has been approved by the Board of Ethics of the GILDRC affiliated to Iran University of medical sciences.

Informed consent

Each individual patient was asked to fill out the consent form.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Motamed, N., Razmjou, S., Hemmasi, G. et al. Lipid accumulation product and metabolic syndrome: a population-based study in northern Iran, Amol. J Endocrinol Invest 39, 375–382 (2016). https://doi.org/10.1007/s40618-015-0369-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-015-0369-5

Keywords

  • Metabolic syndrome
  • Lipid accumulation product
  • Cutoff point